Sabril Approved for Younger Patients With Complex Partial Seizures
Treatment with vigabatrin carries the risk of permanent vision loss.
Seizure Disorders
MPR Weekly Dose Podcast: Episode 17
In our first episode of 2020 we cover new management guidelines in osteoarthritis; Recommendations for the use of testosterone therapy; The best diets for 2020; Two drug recalls; And a new drug approved for the treatment of migraines.
Valtoco Nasal Spray Approved for Seizure Clusters
The FDA has approved Valtoco (diazepam nasal spray; Neurelis) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.
Lamotrigine Recalled Due to Cross-Contamination With Hypertension Med
Taro Pharmaceuticals announced the voluntary recall of 1 lot of lamotrigine 100mg tablets to the consumer level due to cross-contamination with a small amount of enalapril maleate.
New Drugs Approved in 2019
This slideshow gives you an at-glance view of all the new drug approvals in 2019. For the latest drug approvals visit our New Drug Products page.
Antiepileptic Drug Exposure Low in Breastfeeding Infants
Median percentage of infant-to-mother AED concentration ranged from 0.3 to 44.2 percent
Fenfluramine Reduces Convulsive Seizures in Dravet Syndrome
Drop in monthly frequency of convulsive seizures significantly greater with fenfluramine versus placebo
Purified CBD May Help Treat Drug-Resistant Epilepsy
Those taking CBD versus placebo had greater reduction in seizures associated with tuberous sclerosis complex
New Drug Product: Nayzilam
This slideshow shows drug information for Nayzilam. Click here for the complete Nayzilam monograph.
Three Meds Equal as Second-Line Therapy for Status Epilepticus
Levetiracetam, fosphenytoin, valproate treat seizures unresponsive to benzodiazepine in children, adults.
